NASDAQ:FONR

FONAR Competitors

$17.62

-0.29 (-1.62 %)

(As of 04/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$17.53

Now: $17.62▼

$18.05

50-Day Range

$17.79

MA: $18.87▼

$20.35

52-Week Range

$16.59

Now: $17.62▼

$26.49

Volume25,883 shs

Average Volume35,471 shs

Market Capitalization$115.48 million

P/E Ratio16.62

Dividend YieldN/A

Beta1.07

FONAR (NASDAQ:FONR) Vs. EDAP, EYES, IRIX, BSGM, NDRA, and SLNO

Should you be buying FONR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to FONAR, including Edap Tms (EDAP), Second Sight Medical Products (EYES), IRIDEX (IRIX), BioSig Technologies (BSGM), ENDRA Life Sciences (NDRA), and Soleno Therapeutics (SLNO).

FONAR vs. Edap Tms Stock

Edap Tms (NASDAQ:EDAP) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Edap Tms and FONAR's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$50.23 million	4.84	$1.69 million	$0.06	138.83
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A

FONAR has higher revenue and earnings than Edap Tms.

Institutional and Insider Ownership

62.1% of FONAR shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Edap Tms and FONAR's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edap Tms	-4.03%	-11.54%	-5.78%
FONAR	8.28%	5.57%	3.99%

Analyst Ratings

This is a breakdown of recent ratings for Edap Tms and FONAR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	0	0	3	0	3.00
FONAR	0	0	0	0	N/A

Edap Tms currently has a consensus price target of $12.50, suggesting a potential upside of 50.06%. Given Edap Tms' higher possible upside, research analysts plainly believe Edap Tms is more favorable than FONAR.

Summary

FONAR beats Edap Tms on 8 of the 12 factors compared between the two stocks.

FONAR vs. Second Sight Medical Products Stock

Second Sight Medical Products (NASDAQ:EYES) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Second Sight Medical Products and FONAR, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Second Sight Medical Products	0	0	0	0	N/A
FONAR	0	0	0	0	N/A

Profitability

This table compares Second Sight Medical Products and FONAR's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Second Sight Medical Products	N/A	-977.63%	-291.02%
FONAR	8.28%	5.57%	3.99%

Institutional & Insider Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Second Sight Medical Products and FONAR's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Second Sight Medical Products	$3.38 million	60.60	$-33,590,000.00	($1.91)	-3.84
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A

FONAR has higher revenue and earnings than Second Sight Medical Products.

Volatility & Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Summary

FONAR beats Second Sight Medical Products on 7 of the 10 factors compared between the two stocks.

FONAR vs. IRIDEX Stock

FONAR (NASDAQ:FONR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares FONAR and IRIDEX's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A
IRIDEX	$43.45 million	2.53	$-8,810,000.00	($0.64)	-11.05

FONAR has higher revenue and earnings than IRIDEX.

Insider and Institutional Ownership

62.1% of FONAR shares are held by institutional investors. Comparatively, 32.6% of IRIDEX shares are held by institutional investors. 8.6% of FONAR shares are held by insiders. Comparatively, 2.0% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares FONAR and IRIDEX's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FONAR	8.28%	5.57%	3.99%
IRIDEX	-21.54%	-38.60%	-24.99%

Volatility & Risk

FONAR has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for FONAR and IRIDEX, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FONAR	0	0	0	0	N/A
IRIDEX	0	0	2	0	3.00

IRIDEX has a consensus price target of $6.50, indicating a potential downside of 8.06%. Given IRIDEX's higher probable upside, analysts plainly believe IRIDEX is more favorable than FONAR.

Summary

FONAR beats IRIDEX on 8 of the 12 factors compared between the two stocks.

FONAR vs. BioSig Technologies Stock

FONAR (NASDAQ:FONR) and BioSig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares FONAR and BioSig Technologies' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A
BioSig Technologies	N/A	N/A	$-34,060,000.00	N/A	N/A

FONAR has higher revenue and earnings than BioSig Technologies.

Insider and Institutional Ownership

62.1% of FONAR shares are held by institutional investors. Comparatively, 18.3% of BioSig Technologies shares are held by institutional investors. 8.6% of FONAR shares are held by insiders. Comparatively, 19.5% of BioSig Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares FONAR and BioSig Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FONAR	8.28%	5.57%	3.99%
BioSig Technologies	N/A	-244.64%	-213.88%

Volatility & Risk

FONAR has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, BioSig Technologies has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for FONAR and BioSig Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FONAR	0	0	0	0	N/A
BioSig Technologies	0	0	0	0	N/A

Summary

FONAR beats BioSig Technologies on 6 of the 8 factors compared between the two stocks.

FONAR vs. ENDRA Life Sciences Stock

ENDRA Life Sciences (NASDAQ:NDRA) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and target prices for ENDRA Life Sciences and FONAR, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	0	0	0	0	N/A
FONAR	0	0	0	0	N/A

Profitability

This table compares ENDRA Life Sciences and FONAR's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-492.76%	-288.58%
FONAR	8.28%	5.57%	3.99%

Insider and Institutional Ownership

2.8% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 9.6% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares ENDRA Life Sciences and FONAR's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	$10,000.00	9,152.00	$-13,310,000.00	($2.34)	-0.94
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A

FONAR has higher revenue and earnings than ENDRA Life Sciences.

Risk & Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Summary

FONAR beats ENDRA Life Sciences on 7 of the 10 factors compared between the two stocks.

FONAR vs. Soleno Therapeutics Stock

FONAR (NASDAQ:FONR) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for FONAR and Soleno Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FONAR	0	0	0	0	N/A
Soleno Therapeutics	0	0	3	0	3.00

Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 687.88%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than FONAR.

Profitability

This table compares FONAR and Soleno Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FONAR	8.28%	5.57%	3.99%
Soleno Therapeutics	N/A	-88.69%	-51.63%

Insider & Institutional Ownership

62.1% of FONAR shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares FONAR and Soleno Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FONAR	$85.69 million	1.35	$8.24 million	N/A	N/A
Soleno Therapeutics	N/A	N/A	$-30,770,000.00	($0.70)	-1.57

FONAR has higher revenue and earnings than Soleno Therapeutics.

Volatility & Risk

FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

FONAR beats Soleno Therapeutics on 8 of the 11 factors compared between the two stocks.